(MENAFN- ProactiveInvestors - Australia) Cellmid (ASX: CDY) chief executive officer Maria Halasz has topped up her shareholding in the company with the purchase of a further 630,000 shares on-market.
Halasz acquired the shares for a total consideration of A$10,080, or $0.016 per share.
Since the Australian launch of Cellmid's hair growth products in June, the company has generated revenues of $275,000 from sales of the product.
The company, through its controlled entity Advangen International Pty Ltd, previously struck agreement with almost 700 Australian pharmacies to stock its scientifically validated évolis® hair growth product range â€" well above its projected target of 400 stockists by June 2013.
Stockists include some of the largest pharmacy banner groups such as Priceline, Terry White and regional groups like National Pharmacies and their respective online stores.
évolis® is the first Therapeutic Goods Administration-listed topical hair growth product in 24 years.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.